Cognition Therapeutics reports 2024 net loss of $34M; highlights positive Phase 2 data for zervimesine

COGNITION THERAPEUTICS INC

Cash and equivalents $25.0M at Dec 31 2024; $50.0M in NIA grant funds remaining.
Net loss $34.0M ($0.86 per share) vs $25.8M ($0.86) in 2023; R&D expense $41.7M.
Phase 2 SHIMMER DLB study: up to 91% slowing vs placebo across behavior, cognition, function, movement.
Phase 2 SHINE Alzheimer's subgroup with lower p-tau217 showed near-total preservation of cognition.
Plans to request end-of-Phase 2 FDA meetings in Q2 2025 for DLB and Alzheimer's; cash runway into Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.